OptimumBank Holdings heads into its Q1 2026 earnings tomorrow with the most bullish analyst setup it has seen in months — and the short side looking increasingly thin.
The standout this week is the timing of the analyst upgrade. Compass Point's Merrill Ross moved the stock to Buy from Neutral on May 13, just hours before the Q1 print, lifting the price target to $6.50 from $6.00. That follows an initiation from Alliance Global Partners in early April, also at Buy with a $6.50 target. Every covering analyst now rates OPHC a Buy — three out of three — with a consensus target of $7.17. At a current price of $5.50, that implies roughly 24% upside to the average target, and the target-to-price relationship looks internally consistent for a micro-cap bank trading at a P/E around 5.5x and a P/B below 0.9x. Cheap by almost any traditional bank valuation measure. OPHC's factor score for analyst recommendation divergence ranks at the 92nd percentile of the universe — a signal that the Street's view is materially more constructive than the broader consensus would suggest for a name this size.
Short positioning is almost a non-story here, which itself tells you something. Short interest amounts to just 0.06% of the free float — a negligible level that hasn't generated meaningful pressure at any point in the past month. More notably, shorts have been exiting at pace: SI has dropped more than 53% over the past 30 days and fell nearly 39% this week alone. The borrow market reflects this disengagement. Cost to borrow has more than halved since mid-March, now running around 2.9% from above 4.5% in late March. Availability is extremely loose — with utilization barely above 0.25%, nearly the entire lending pool remains untouched. There is no squeeze narrative here. Shorts were never crowded in, and now they're less present than ever.
Earnings history offers modest but readable context. Over the four most recent events, the stock's one-day reaction has swung between -4.4% and +2.4%. The average is barely negative. The five-day drift has been more volatile, ranging from -5.7% to +4.0%. Nothing in the pattern suggests a reliably directional reaction — the market has repriced both ways after results, and often by small margins.
The ownership structure is concentrated and illiquid. Michael Blisko holds over 9% of shares. Moishe Gubin, the independent chairman, holds another 6.5%. Together with a handful of other insiders and micro-cap funds — AllianceBernstein, Vanguard, and Renaissance each hold a few percent — the float is narrow and the register tightly held. The most recent notable insider trade on file is a CEO sale of approximately $186k in February, flagged as stale given it falls outside the 90-day window. No fresh insider buying is on record in the current period.
With a market cap of roughly $67 million, one analyst just upgraded to Buy on the morning of the earnings release, and short interest near historical lows, the setup going into tomorrow's Q1 report is defined less by positioning pressure and more by whether the earnings delivery can justify the gap between a $5.50 price and a $7.17 consensus target.
See the live data behind this article on ORTEX.
Open OPHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
